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ABSTRACT
Aims/Introduction: A dietary supplementation product enriched with glutamine,
dietary fiber and oligosaccharide (GFO) is widely applied for enteral nutrition support in
Japan. The aim of the present study was to evaluate the effects of GFO ingestion on
secretion of incretins, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1
(GLP-1), and glucagon-like peptide-2 (GLP-2).
Materials and Methods: We carried out a cross-over study involving 20 healthy Japa-
nese volunteers. The participants received GFO or 17 g of glucose, the equivalent carbo-
hydrate in GFO as the control. Plasma glucose, serum insulin, and plasma total GIP, total
GLP-1 and total GLP-2 levels during GFO or glucose loading were determined.
Results: GFO loading produced significantly higher plasma GLP-1 levels at 30 min and
60 min, area under the curve-GLP-1 value, and area under the curve-GLP-2 value after
administration compared with those by glucose loading. In contrast, plasma GIP levels at
both 30 and 60 min, and area under the curve-GIP value after glucose loading were
significantly higher than those after GFO loading.
Conclusions: These results show that GFO ingestion stimulates GLP-1 and GLP-2 secre-
tion, and reduces GIP secretion compared with glucose ingestion. Therefore, GFO could
have an intestinotrophic effect as well as an ameliorating effect on metabolic disorders
through modification of release of gut hormones.
INTRODUCTION
Various hormones secreted from diverse enteroendocrine cells
in the gastrointestinal tract regulate nutrient absorption and
metabolism in the intestinal environment1. Gastric inhibitory
polypeptide (GIP) secreted from K-cells in the proximal small
intestine and glucagon-like peptide-1 (GLP-1) secreted from
L-cells in the distal small intestine and colon, respectively, are
recognized as incretins, which amplify insulin secretion from
pancreatic b-cells glucose-dependently. Incretins are responsible
for approximately half of the postprandial insulin secretion2,3. It
is well known that not only carbohydrate, but also fat and pro-
tein ingestion, stimulate incretin secretion4,5. Previous studies
have shown that GIP secretion is higher after mixed meal (con-
taining carbohydrate, fat, and protein) loading compared with
that by oral glucose loading6,7. In contrast, the GLP-1 secretory
response is not signiﬁcantly different between oral glucose load-
ing and mixed meal loading6,7. These ﬁndings suggest that GIP
secretion is more susceptible than GLP-1 secretion to nutri-
tional composition.
GLP-1 and glucagon-like peptide-2 (GLP-2) are progluca-
gon-derived peptides secreted simultaneously from intestinal
L-cells in response to meal ingestion1. GLP-2 has no such insu-
linotropic effect, but has other various biological effects on the
intestine, including stimulation of intestinal mucosal growth8,9,
inhibition of gastric acid secretion10, enhancement of intestinal
epithelial barrier function11, and upregulation of sodium-glucose
cotransporter 1 (SGLT-1) transport activity12 and intestinal
blood ﬂow13–15. Thus, GLP-2 is known as an intestinotrophic
hormone. Processing of proglucagon in the intestine generates
equimolar amounts of GLP-1 and GLP-2. A sampling study of
the mesenteric circulation draining the intestinal bed has
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conﬁrmed that GLP-1 and GLP-2 are secreted at an equal rate
(1:1)16.
A dietary supplementation product enriched with glutamine,
dietary ﬁber and oligosaccharide (GFO; Otsuka Pharmaceuti-
cal Co., Ltd., Tokyo, Japan) is widely applied for enteral nutri-
tion support in Japan. Glutamine, the most abundant
component of GFO, is one of the major fuel sources for intesti-
nal cells17–19. Amino acids, especially glutamine, have been
shown to stimulate incretin secretion20–24. In fact, a previous
report showed that glutamine treatment before meal ingestion
augmented the GLP-1 response and reduced postprandial glyce-
mia in type 2 diabetes patients, with effectiveness comparable
with that of the DPP-4 inhibitor, sitagliptin25. The dietary ﬁbers
contained in GFO are polydextrose and hydrolyzed guar gum,
which are water-soluble. The oligosaccharide contained in GFO
is lactosucrose, a kind of galacto-oligosaccharide. Fiber and oli-
gosaccharide are prebiotics that stimulate the growth and activ-
ity of gastrointestinal microﬂora. It is known that short-chain
fatty acids (SCFA)26, which are produced by ingestion of die-
tary ﬁber and some kinds of oligosaccharide, promote GLP-1
secretion. In our recent report, we found that plasma GLP-1
levels were much higher in GFO-administered mice than in
glucose-administered mice27. In the present report, we show
that GFO alleviates experimental colitis in mice27. In addition,
it is reported that GFO prevents gut bacterial translocation in
an experimental intestinal infection model28. Thus, it is estab-
lished that GFO has protective effects on the intestinal tract.
We speculate that GFO stimulates release of GLP-2, an intesti-
notrophic hormone, along with GLP-1 secretion to attenuate
development of mucosal damage.
To date, there is no assessment of the effects of GFO on
GLP-2 secretion. Additionally, there is no report on the effect
of dietary supplementation products, such as GFO, on the
secretion of incretins. The aim of the present study was to eval-
uate incretin (GIP and GLP-1) and GLP-2 secretion in
response to GFO administration, in comparison with the
administration of glucose in an equivalent amount of carbohy-
drate to that in GFO.
MATERIALS AND METHODS
Participants
A total of 20 healthy Japanese volunteers (10 men and 10
women) were recruited into the present study. The participants
had no history of hypertension, hyperlipidemia or kidney and
liver disease, and did not take any drugs during the 2 weeks
before the study. The study was designed in compliance with
the ethics regulations of the Helsinki Declaration and Kyoto
University. Informed consent was obtained from all partici-
pants.
Study Design
We carried out a randomized cross-over design experiment
with two single oral loadings: GFO loading and glucose loading.
The participants’ age, height and bodyweight were determined.
Blood samples for measurement of liver and kidney function,
glycated hemoglobin (HbA1c; National Glycohemoglobin Stan-
dardization Program [NGSP]), triglycerides (TG), total choles-
terol and high-density lipoprotein (HDL) cholesterol levels were
drawn after an overnight fast. After the participants fasted over-
night for 10–16 h, they received three packs of GFO
(1 pack = 36 kcal; protein 3.6 g, fat 0 g, carbohydrates 6.01 g,
ﬁber 5.0 g, Na 0.2–12 mg, galactsyl-scurose 1.45 g, glutamine
3.0 g) dissolved in water or water-dissolved 17 g of glucose,
which is an equivalent amount of the carbohydrate in GFO, as
control (54 kcal). The carbohydrates contained in GFO, exclud-
ing lactosucrose and ﬁber, are composed mainly of dextrin and
sucrose. Blood samples were collected at 0, 30, 60, 120 and
180 min after GFO or glucose loading, and were centrifuged at
1,880 g at 4°C for 10 min. After collecting supernatant of the
samples, plasma and serum were stocked at -80°C. Blood was
distributed into chilled tubes containing ethylenediaminetetra-
acetic acid and aprotinin (500 kIU/mL blood, Trasylol; SRL
Inc., Tokyo, Japan) for analyses of GIP, GLP-1 and GLP-2.
Plasma glucose (PG), serum insulin (IRI), serum C-peptide
(CPR), serum triglyceride (TG), plasma total incretin (GIP and
GLP-1) and GLP-2 levels were measured at the indicated times.
Analytical Methods
The PG levels were measured by the glucose oxidase method.
Serum IRI and CPR levels were measured by enzyme-linked
immunosorbent assay. TG levels were measured by enzymatic
method (free glycerol elimination method). HbA1c was mea-
sured using high-performance liquid chromatography (HPLC)
and are expressed as a NGSP value calculated by the formula:
HbA1c (NGSP value) (%) = 1.02 9 HbA1c (Japan Diabetes
Society (JDS) value) (%) + 0.2529. Homeostasis model assess-
ment of insulin resistance (HOMA-IR), HOMA of b-function
(HOMA-b), and insulinogenic index were evaluated as basal
insulin resistance, basal insulin secretion and early phase insulin
secretion, respectively30–32. Total GIP and total GLP-1 levels
were measured using a human GIP ELISA kit (Merck Millipore
Corp, Bilerica, MA, USA) and human GLP-1 ELISA kit (Meso
Scale Discovery, Gaithersburg, MD, USA), respectively33. Total
GLP-2 levels were measured using a human GLP-2 ELISA kit
(Phoenix Pharmaceuticals, Burlingame, USA)34.
Calculations and Statistical Analysis
A repeated-measures ANOVA was carried out with SPSS (version
17; SPSS Inc., Chicago, IL, USA). If a signiﬁcant interaction of
treatment and time was detected, values at single time-points
were compared by one-way ANOVA with Bonferroni’s post-hoc
test. The area under the curve of PG (AUC-PG), IRI (AUC-
IRI), CPR (AUC-CPR), TG (AUC-TG), total GIP (AUC-GIP),
total GLP-1 (AUC-GLP-1) and total GLP-2 (AUC-GLP-2) were
calculated by the trapezoidal rule. Statistical differences in val-
ues of AUCs were analyzed using Student’s t-test. P-values
<0.05 were considered statistically signiﬁcant. Data are pre-
sented as mean – standard error.
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RESULTS
The proﬁles of the participants are shown in Table 1. Mean age
was 32.2 – 2.0 years, and mean body mass index was
22.4 – 0.8 kg/m2. HOMA-b and HOMA-IR were 111 – 15 and
1.2 – 0.8, respectively. No participants had liver or kidney dys-
function (data not shown). HbA1c, TG, total cholesterol and LDL
cholesterol levels were within normal limits in the fasting state.
The proﬁles of PG, IRI, and CPR in GFO loading and glu-
cose loading are shown in Figure 1. Fasting concentrations of
PG (Figure 1a), IRI (Figure 1c), and CPR (Figure 1e) did not
differ between GFO loading and glucose loading. At 30 min
after glucose loading, PG was signiﬁcantly higher than that after
GFO loading (GFO 112.7 – 3.2 mg/dL vs glucose
129.8 – 4.1 mg/dL, P < 0.01; Figure 1a). AUC-PG in glucose
loading was signiﬁcantly higher than those in GFO loading
(GFO 15,221 – 255 mg/dL 9 min vs glucose 16,009 – 375
mg/dL 9 min, P < 0.05; Figure 1b). IRI and TG showed no
signiﬁcant differences at each time-point between either loading
(Figure 1c,g). At 30 min after glucose loading, CPR was signiﬁ-
cantly higher than after GFO loading (GFO 3.6 – 0.3 mg/dL vs
glucose 4.2 – 0.3 mg/dL, P < 0.05; Figure 1e), whereas AUC-
IRI, AUC-CPR and AUC-TG were similar in both loading
groups (Figure 1d,f,h).
Plasma GLP-1 levels were signiﬁcantly higher in GFO load-
ing than in glucose loading at 30 min (GFO 26.5 – 2.4 pg/mL
vs glucose 21.1 – 1.9 pg/mL, P < 0.05) and 60 min (GFO
22.1 – 1.8 pg/mL vs glucose 12.1 – 1.4 pg/mL, P < 0.01;
Figure 2a). AUC-GLP-1 in GFO loading was signiﬁcantly
higher than that in glucose loading (GFO 3,371 – 344 pg/
mL 9 min vs glucose 2,445 – 272 pg/mL 9 min, P < 0.01;
Figure 2b). Plasma GIP levels were signiﬁcantly higher in
glucose loading than in GFO loading at 30 min (GFO
89.7 – 5.8 pg/mL vs glucose 126.7 – 11.1 pg/mL, P < 0.01)
and 60 min (GFO 66.0 – 3.2 pg/mL vs glucose 84.3 – 4.9 pg/
mL, P < 0.01; Figure 2c). AUC-GIP in glucose loading was sig-
niﬁcantly higher than in GFO loading (GFO 11,206 – 450 pg/
mL 9 min vs glucose 13,077 – 671 pg/mL 9 min, P < 0.01;
Figure 2d). Plasma GLP-2 levels showed no signiﬁcant differ-
ence at each time-point between glucose and GFO loading (Fig-
ure 2e); however, the time-course of GLP-2 differed between
the two groups (sample 9 time, P < 0.01). Additionally, AUC-
GLP-2 in GFO loading was signiﬁcantly higher than in glucose
loading (GFO 756.4 – 78.1 ng/mL 9 min vs glucose
618.6 – 66.9 ng/mL 9 min, P < 0.01; Figure 2f).
DISCUSSION
In the present study, we evaluated incretins (GIP and GLP-1)
and GLP-2 levels in response to single administration of GFO or
Table 1 | Characteristics of the participants
n (male/female) 20 (10/10)
Age (years) 32.2 – 2.0
BMI (kg/m2) 22.4 – 0.8
HbA1c (%) 5.2 – 0.1
HOMA-b 111 – 15
HOMA-IR 1.2 – 0.8
Total cholesterol (mg/dL) 190.5 – 7.6
Triglycerides (mg/dL) 72.3 – 8.6
LDL cholesterol (mg/dL) 109.3 – 7.0
HDL cholesterol (mg/dL) 60.0 – 3.4
Data presented as mean – standard error. BMI, body mass index;
HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA,
homeostasis model assessment; HOMA-IR, homeostasis model assess-
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Figure 1 | Glucose, insulin, serum C-peptide (CPR), and serum triglyceride (TG) levels during GFO and glucose tolerance. The (a) glucose, (c) insulin,
(e) CPR, and (g) TG levels were measured after oligosaccharide (GFO) and glucose loading. Glucose loading and GFO loading groups are
represented by white circles with dot line and black circles with solid line, respectively. *P < 0.05 versus glucose group. Total glucose and insulin
secretion were evaluated by (b) area under the curve (AUC)-glucose, (d) AUC-insulin, (f) AUC-CPR, and (h) AUC-TG, respectively. Glucose loading
and GFO loading groups are represented by white and black squares, respectively. *P < 0.05
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glucose equivalent to the amount of carbohydrate in GFO. GFO
loading produced signiﬁcantly higher plasma GLP-1 levels at 30,
60 and 120 min after administration, as well as higher AUC
values compared with those by glucose loading. In contrast, both
plasma GIP levels at 30 and 60 min, and AUC values were sig-
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Figure 2 | Incretin and glucagon-like peptide-2 (GLP-2) levels during oligosaccharide (GFO) and glucose tolerance. Total (a) glucagon-like peptide-1
(GLP-1), (c) total gastric inhibitory polypeptide (GIP), and (e) total GLP-2 levels were measured after GFO and glucose loading. Glucose loading and
GFO loading groups are represented by white circles with dotted line and black circles with solid line. *P < 0.05, **P < 0.01 versus glucose group.
GLP-1, GIP, and GLP-2 secretion were evaluated by (b) AUC-GLP-1, (d) AUC-GIP and (f) AUC-GLP-2, respectively. Glucose loading and GFO loading
groups are represented by white and black squares, respectively. **P < 0.01
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GFO is composed of glutamine, dietary ﬁber and oligosac-
charide. Glutamine has been shown to stimulate GLP-1 secre-
tion20–22. Our ﬁnding in the present study of higher plasma
GLP-1 levels after GFO loading might well reﬂect the GLP-1
secretory effects of glutamine. Although glutamine also
increases plasma GIP levels, it is less effective than glucose20.
Our ﬁndings on plasma GIP levels are in accord with this
ﬁnding.
The dietary ﬁbers contained in GFO are polydextrose and
hydrolyzed guar gum, which are water-soluble. Previous studies
have shown that the glycemic response is markedly ﬂattened by
polydextrose or guar gum ingestion35,36. It was also reported
that the plasma GIP concentration is signiﬁcantly reduced after
ingestion of guar gum bread compared with control bread con-
taining an equal amount of carbohydrate35. GFO also contains
dextrin, one of the polysaccharides, for which absorption is
much delayed compared with glucose. These ﬁndings consid-
ered together suggest that more carbohydrate might pass the
K-cells of the proximal small intestine and reach the L-cells in
the lower intestine, resulting in less GIP response and greater
GLP-1 response after administration of GFO compared with
those after glucose administration.
The oligosaccharide contained in GFO is lactosucrose, a kind
of galacto-oligosaccharide. As well as being a soluble ﬁber, it is
known that lactosucrose is a prebiotic that produces SCFAs,
such as acetate, propionate and butyrate, in the colon by anaer-
obic bacterial fermentation37. A previous study suggested that
SCFAs stimulate GLP-1 secretion through GPR43 and
GPR4126. However, unlike the case of long-term administration,
a single oral administration of GFO was carried out in the
present study, which should not affect anaerobic bacterial fer-
mentation. GFO also contains sucralose, the artiﬁcial sweetener,
but a previous study has found that sucralose ingestion does
not stimulate either GLP-1 or GIP release38.
Processing of proglucagon in the intestine generates equimo-
lar amounts of GLP-1 and GLP-2 concomitantly. A sampling
study of the mesenteric circulation draining the intestinal bed
conﬁrmed that GLP-1 and GLP-2 are secreted at an equal rate
(1:1)16. In the present study, compared with that by glucose
loading, plasma GLP-2 levels were signiﬁcantly higher after
30 min of GFO loading, which was accompanied by higher
plasma levels of GLP-1, suggesting that GFO stimulates GLP-2
secretion by the same mechanism as that by GLP-1 secretion.
The metabolic clearance rate of GLP-2 is slower than that of
GLP-139. Thus, the basal blood level of GLP-2 could be rela-
tively higher than that of GLP-1, masking the impact of GFO
on GLP-2 levels. Our observations also accord with previous
reports that the serum GLP-2 level is relatively higher than that
of the GLP-1 level40,41. We previously found that plasma GLP-
1 levels are higher in GFO-administered mice than those in
glucose-administered mice, and that GFO alleviates experimen-
tal colitis in mice27.
A previous study showed that GLP-2 stimulates intestinal
apoB48-containing lipoprotein secretion in mice, possibly
through the increased lipid uptake42. In that study, blood TG
levels also were increased along with apoB48 secretion by GLP-
2 administration. However, in the present study, no signiﬁcant
differences were observed in TG levels between either loading
(Figure 1g). It is possible that this inconsistent result depends
on the presence or absence of oil in the loading test. The previ-
ous study administered olive oil (200 lL/mice) to mice with
GLP-2 injection42. In contrast, we did not include any oil in
the loading test in the present study. We also carried out the
loading test after participants fasted overnight for 10–16 h.
The present results clearly show that GFO ingestion stimu-
lates GLP-1 and GLP-2 secretion, and represses GIP secretion
compared with simple glucose loading. Previous reports have
established the crucial role of GIP in linking overnutrition to
obesity43,44. We recently reported that chronic reduction of GIP
secretion ameliorates high-fat diet-induced obesity and insulin
resistance45. In addition, treatment of type 2 diabetes with
GLP-1 receptor agonists is associated with reductions of
HbA1c, fasting plasma glucose and bodyweight46. We therefore
expected that reducing the GIP effect and stimulating the GLP-
1 effect by functional foods, such as GFO, could have desirable
effects on glucose and/or lipid metabolic abnormality. However,
in the present study, the contribution ratio of each component
of GFO to the PG levels and the secretion patterns remains
unclear; separate, single-nutrient administration studies are
required. In addition, oil and GFO co-loading test is required
to determine whether or not GFO loading increases lipid
uptake through an increase of GLP-2 secretion.
In conclusion, we showed that a combination of glutamine,
dietary ﬁber and GFO provides intestinal protection, and is also
effective for metabolic disorders through modiﬁcation of gut
hormone release.
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